PET-CT monitoring in the treatment of pancreatic cancer
https://doi.org/10.37748/2687-0533-2020-1-4-7
Abstract
Pancreatic cancer is a disease characterized by low visualization, high metastasis, and lethality. The average life expectancy for this nosology is less than 1 year. Early diagnosis of pancreatic cancer is difficult due to the lack of specific symptoms. As a rule, at the time of tumor visualization, every third patient has regional lymph nodes involved in the process, and every second patient already has distant metastases. We present a clinical case of a 73-year-old patient with a diagnosis of: cancer of the pancreatic head St IV, T4N1M1. The woman's primary positron emission tomography (PET-CT) revealed a metabolically active lesion with a size of 26х21х32 mm. After the combined multistage therapy under the control of PET-CT, it was possible to achieve complete leveling of the primary tumor focus and a relapse-free course of the disease for 11 months.
Our clinical observation showed the effectiveness of dynamic control (using PET-CT) treatment of metastatic pancreatic cancer, which influenced the patient's treatment strategy.
Conclusion. Patients with pancreatic adenocarcinoma ECOG ≥ 3, despite the prevalence of the process, should be offered comprehensive treatment.
About the Authors
G. E. Roitberg
I.Pirogov Russian National Research Medical University (RNRMU); Medicina
Russian Federation
Russian Federation
Grigory E. Roitberg - Dr. Sci. (Med.), professor, academician of the RAS, head of the Department of therapy, general medical practice and nuclear medicine of faculty of additional professional education of N.I.Pirogov RNRMU; President of the clinic Medicina, SPIN: 1032-9122, Author ID: 218525.
Ostrovityanova str., Moscow 117997; 2nd Tverskaya-Yamskaya lane, Moscow125047
O. Yu. Anikeeva
Medicina
Russian Federation
Russian Federation
2nd Tverskaya-Yamskaya lane, Moscow125047
References
1. Хатьков И.Е. Стратегия лечения рака поджелудочной железы на современном этапе. Анналы хирургической гепатологии. 2019;24(3):110-114.
2. Strobel O, Buchler MW. Pancreatic cancer: Clinical practice guidelines - what is the evidence? Nat Rev Clin Oncol. 2016;13(10):593-594. https://doi.org/10.1038/nrclinonc.2016.127
3. Франциянц Е.М., Кит О.И., Алейнов В.И., Горошинская И.А. Биомаркеры, неоангиогенез и факторы роста при раке поджелудочной железы. Исследования и практика в медицине. 2019;6(3):51-64. https://doi.org/10.17709/2409-2231-2019-6-3-5
4. Sohal DPS, Kennedy EB, Khorana A, Copur MS, Crane CH, Garrido-Laguna I, et al. Metastatic Pancreatic Cancer: AS- CO Clinical Practice Guideline Update. J Clin Oncol. 2018 20;36(24):2545-2556. https://doi.org/10.1200/JCO.2018.78.9636
5. Москвичева Л.И., Петров Л.О., Сидоров Д.В. Возможности современных методов абляции при нерезектабельном местно-распространенном раке поджелудочной железы. Исследования и практика в медицине. 2018;5(2):86-99. https://doi.org/10.17709/2409-2231-2018-5-2-10
6. Chiorean EG, Coveler AL. Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. Drug Des Devel Ther. 2015;9:3529-3545. https://doi.org/10.2147/DDDT.S60328
7. Дубцова Е.А., Винокурова Л.В., Никольская К.А., Агафонов М.А. Заболевания поджелудочной железы - трудности дифференциальной диагностики. Трудный пациент. 2014;12(12):18-21.
8. Геворкян Т.Г., Файнштейн И.А. Паллиативная панкреатодуоденальная резекция при раке головки поджелудочной железы. Исследования и практика в медицине. 2018;5(1):52-59. https://doi.org/10.17709/2409-2231-2018-5-1-6
9. Ройтберг Г.Е., Тюлькина Е.Е., Дорош Ж.В., Филатов Р.Е., Аникеева О.Ю. Организация мультидисциплинарной реабилитации пациентов онкологического профиля. Вестник восстановительной медицины. 2019;5(93):14-20.
10. Bosetti C, Bertuccio P, Malvezzi M, Levi F, Chatenoud L, Negri E, et al. Cancer mortality in Europe, 2005-2009, and an overview of trends since 1980. Ann Oncol. 2013 Oct;24(10):2657-2671. https://doi.org/10.1093/annonc/mdt301
11. Ройтберг Г.Е., Кондратова Н.В. Возможности применения зарубежного опыта скрининговых программ с целью улучшения ранней диагностики онкологической патологии. Главврач. 2014;(2):37-46.
12. Zhang J, Zuo C-J, Jia N-Y, Wang J-H, Hu S-P, Yu Z-F, et al. Cross-modality PET/CT and contrast-enhanced CT imaging for pancreatic cancer. World J Gastroenterol. 2015 Mar 14;21(10):2988-2996. https://doi.org/10.3748/wjg.v21.i10.2988
13. Kauhanen SP, Komar G, Seppanen MP, Dean KI, Minn HR, Kajander SA, et al. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomog-raphy/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg. 2009 Dec;250(6):957-963. https://doi.org/10.1097/SLA.0b013e3181b2fafa
14. Dibble EH, Karantanis D, Mercier G, Peller PJ, Kachnic LA, Subramaniam RM. PET/CT of cancer patients: part 1, pancreatic neoplasms. AJR Am J Roentgenol. 2012 Nov;199(5):952-967. https://doi.org/10.2214/AJR.11.8182
15. Kitajima K, Murakami K, Yamasaki E, Kaji Y, Shimo-da M, Kubota K, et al. Performance of integrated FDG-PET/ contrast-enhanced CT in the diagnosis of recurrent pancreatic cancer: comparison with integrated FDG-PET/ non-contrast-enhanced CT and enhanced CT. Mol Imaging Biol. 2010 Aug;12(4):452-459. https://doi.org/10.1007/s11307-009-0271-7
Review
For citations:
Roitberg G.E., Anikeeva O.Yu. PET-CT monitoring in the treatment of pancreatic cancer. South Russian Journal of Cancer. 2020;1(4):54-60. https://doi.org/10.37748/2687-0533-2020-1-4-7
Views:
2000
Email this article 